PCV (13-valent or 15-valent, adsorbed): patient group direction (PGD) template
PGD template to support the national pneumococcal polysaccharide conjugate vaccine (13-valent or 15-valent, adsorbed) (PCV) vaccination programme.
Applies to England
Documents
Details
This patient group direction (PGD) template is to support the administration of pneumococcal polysaccharide conjugate vaccine (13-valent or 15-valent, adsorbed) (PCV13 or PCV15) to individuals from 12 weeks to under 2 years of age in accordance with the national immunisation programme.
The PCV PGD version 6.0 is valid from 1 July 2025 to 31 May 2027.
Practitioners must not use thisĀ PGDĀ template until it has been authorised in Section 2. This is a legal requirement (seeĀ . Practitioners should follow local policy/procedures to access authorisedĀ PGDĀ documents.
This PGD template should be used with reference to current national guidance, the Green Book, and for the vaccine.
Updates to this page
-
Added version 6 - see page 3 for change history.
-
Added version 5.00 - see page 3 for change history.
-
Added version 04.00 - see change history on page 2.
-
Added V03.00: updated PGD for the PCV 1+1 routine schedule for infants born on or after 1 Jan 2020.
-
Added updated PGD template: validity from 6 weeks of age and addition of outbreak indication.
-
Added notice of extension for PCV (13-valent, adsorbed) patient group direction.
-
First published.